Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Fixed-Sequence 2-Period Crossover Study Of Palbociclib In Healthy Subjects To Investigate The Potential Effect Of Antacid Treatment On The Pharmacokinetics Of A Single Oral Dose Administered Under Fasted Conditions

Next Previous
Search
Trial Profile

A Phase 1, Open-Label Fixed-Sequence 2-Period Crossover Study Of Palbociclib In Healthy Subjects To Investigate The Potential Effect Of Antacid Treatment On The Pharmacokinetics Of A Single Oral Dose Administered Under Fasted Conditions

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary) ; Rabeprazole
  • Indications Breast cancer; Colorectal cancer; Gastro-oesophageal reflux; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Peptic ulcer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Pfizer

Most Recent Events

  • 01 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 01 Sep 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
  • 09 Aug 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top